Curis, Inc. (NASDAQ:CRIS) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.10) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.09) by $0.01, Bloomberg Earnings reports. The company had revenue of $2.10 million during the quarter, compared to the consensus estimate of $2.08 million. Curis had a negative return on equity of 163.29% and a negative net margin of 841.05%. The company’s revenue for the quarter was up 23.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.09) earnings per share.

Curis (NASDAQ CRIS) traded up 15.44% during mid-day trading on Friday, reaching $1.72. 653,870 shares of the company were exchanged. The stock’s 50-day moving average price is $1.98 and its 200-day moving average price is $2.32. Curis has a 1-year low of $1.49 and a 1-year high of $3.72. The stock’s market capitalization is $247.29 million.

Several hedge funds have recently modified their holdings of the company. Bank of America Corp DE increased its stake in shares of Curis by 58.7% in the first quarter. Bank of America Corp DE now owns 36,348 shares of the biotechnology company’s stock worth $101,000 after buying an additional 13,448 shares during the last quarter. Prudential Financial Inc. acquired a new stake in shares of Curis during the first quarter worth about $105,000. Dynamic Technology Lab Private Ltd increased its stake in shares of Curis by 22.3% in the first quarter. Dynamic Technology Lab Private Ltd now owns 41,922 shares of the biotechnology company’s stock worth $117,000 after buying an additional 7,638 shares during the last quarter. State of Wisconsin Investment Board acquired a new stake in shares of Curis during the second quarter worth about $163,000. Finally, BB&T Securities LLC acquired a new stake in shares of Curis during the second quarter worth about $179,000. 51.68% of the stock is owned by hedge funds and other institutional investors.

A number of research firms have recently commented on CRIS. Zacks Investment Research cut shares of Curis from a “hold” rating to a “sell” rating in a report on Wednesday, May 10th. Cowen and Company restated a “buy” rating on shares of Curis in a report on Friday, May 5th. BidaskClub cut shares of Curis from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Finally, ValuEngine upgraded shares of Curis from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. Curis presently has a consensus rating of “Hold” and a consensus target price of $5.88.

WARNING: “Curis, Inc. (NASDAQ:CRIS) Posts Earnings Results, Misses Estimates By $0.01 EPS” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.dailypolitical.com/2017/08/04/curis-inc-nasdaqcris-posts-earnings-results-misses-estimates-by-0-01-eps.html.

About Curis

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Earnings History for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.